Selective α7 nicotinic receptor activation by AZD0328 enhances cortical dopamine release and improves learning and attentional processes

• Published in: Biochemical pharmacology 2009-10, Vol.78 (7), p.880-888
• Main Authors: Sydserff, Simon, Sutton, E.J., Song, Dekun, Quirk, Michael C., Maciag, Carla, Li, Chaoying, Jonak, Gerald, Gurley, David, Gordon, John C., Christian, Edward P., Doherty, James J., Hudzik, Tom, Johnson, Edwin, Mrzljak, Ladislav, Piser, Tim, Smagin, Gennady N., Wang, Yi, Widzowski, Dan, Smith, Jeffrey S.
• Format: Article
• Language: English
• Subjects: Biological and medical sciences; Cognition; Dopamine; Medical sciences; Neuronal nicotinic receptor; Pharmacology. Drug treatments; α7 Agonist; α7 Nicotinic acetylcholine receptor
• ISSN: 0006-2952; 1873-2968
• DOI: 10.1016/j.bcp.2009.07.005

α7 Neuronal nicotinic receptor activation of midbrain dopamine neurons improves selective attention and acquisition of operant and object recognition behaviors. AZD0328, a novel spirofuropyridine neuronal nicotinic receptor partial agonist, was used to investigate the role of α7 neuronal nicotinic receptor (NNR) activation in the modulation of midbrain dopamine neuron function, cortical dopamine release and on two behavioral tasks known to be dependent on optimal levels of cortical dopamine. In vivo recordings from area 10 (ventral tegmental area) in rat brain showed an increased firing of putative dopamine neurons in response to low (0.00138 mg/kg) doses of AZD0328. Bursting patterns of dopamine neuron activity remained largely unchanged by application of AZD0328. In vivo microdialysis in awake rats showed an increase in extracellular prefrontal cortical dopamine in response to low doses of AZD0328. Compound-stimulated dopamine release showed an inverted dose effect relation that was maximal at the lowest dose tested (0.00178 mg/kg). Peak extracellular dopamine levels were reached 2 h after dosing with AZD0328. Acquisition of operant responding with delayed reinforcement in rats was dose dependently enhanced by AZD0328 with a plateau effect measured at 0.003 mg/kg. This effect was blocked by pre-treatment of animals with the selective α7 antagonist methyllycaconitine. AZD0328 improved novel object recognition in mice over a broad range of doses (0.00178–1.78 mg/kg) and the compound effect was found to be absent in homozygous α7 KO animals. Together, these data indicate that selective interaction with α7 NNRs by AZD0328 selectively enhances midbrain dopaminergic neuronal activity causing an enhancement of cortical dopamine levels; these neurochemical changes likely, underlie the positive behavioral responses observed in two different animal models. Our results suggest selective α7 NNR agonists may have significant therapeutic utility in neurologic and psychiatric indications where cognitive deficits and dopamine neuron dysfunction co-exist.